NYSEAMERICAN:CVM Cel-Sci Q2 2026 Earnings Results & Report $1.94 -0.01 (-0.51%) Closing price 10/9/2026 04:10 PM EasternExtended Trading$1.94 0.00 (-0.26%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cel-Sci reported Q2 2026 earnings on May 15, 2026. The company reported EPS of -$0.67. Research:ProfileEarnings History Earnings Announcement Details QuarterQ2 2026Report DateMay 15, 2026TimeAfter Market Closes Cel-Sci EPS ResultsActual EPS-$0.67Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate0 of last 4 quartersCel-Sci Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Cel-Sci Q2 2026 Earnings FAQ Did Cel-Sci beat earnings estimates for Q2 2026? Cel-Sci (NYSEAMERICAN:CVM) reported earnings of -$0.67 per share for Q2 2026. The report was announced on Friday, May 15, 2026. Cel-Sci Earnings HeadlinesCEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and LaryngologySeptember 15, 2026 | finance.yahoo.comCEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and LaryngologySeptember 15, 2026 | businesswire.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 11 at 1:00 AM | Altimetry (Ad)CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory ...August 4, 2026 | finance.yahoo.comCEL-SCI Corporate Event Calendar | AMEX:CVMJuly 16, 2026 | benzinga.comCEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerJuly 13, 2026 | finance.yahoo.comSee More Cel-Sci Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cel-Sci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cel-Sci and other key companies, straight to your email. Email Address About Cel-SciCel-Sci (NYSEAMERICAN:CVM) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company’s lead product candidate is Multikine (leukocyte interleukin, injection), an investigational immunotherapy designed to activate and direct the immune system against cancer cells. Its development has primarily focused on the treatment of locally advanced primary head and neck cancer. Cel-Sci also develops therapies and vaccine candidates using its proprietary LEAPS technology platform. LEAPS, or L.E.A.P.S. (Ligand Epitope Antigen Presentation System), is designed to stimulate targeted immune responses and has been investigated for potential applications in cancer, viral infections, and other diseases. These candidates remain in development and are not broadly marketed as approved products. Founded in 1983, Cel-Sci is headquartered in Vienna, Virginia. The company conducts research and clinical development activities through collaborations and clinical programs in the United States and other countries. Cel-Sci is led by Geert R. Kersten, who serves as chief executive officer.View Cel-Sci ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
